Is it safe?
Can TARS take a bad year?
Tarsus Pharmaceuticals, Inc. holds $377M more cash than debt, so a bad year is a question about profits, not about lenders.
$377M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 7.74
Altman Z-score · safe zone, above 3
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ2 2026
- $73M
- Cash and short-term investments
- $450M
- Net cash
- $377M
- EBITDA, trailing twelve months
- −$47M
- Operating profit, trailing twelve months
- −$49M
- Debt / equity
- 0.21×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −78%
- Below its 52-week high
- −14%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.